Bridgefront Capital’s Nuvalent NUVL Stock Holding History

Bridgefront Capital’s Portfolio NUVL Stock Details NUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,053	Closed	-$358K	–	773
2025 Q1	$358K	Buy	+5,053	New	+$395K	0.1%	344

Other funds holding NUVL

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bridgefront Capital's NUVL Position: Q2 2025 in Review

Bridgefront Capital sold out of Nuvalent (NUVL) in Q2 2025, closing a stake of 5,053 shares — an estimated $358K sold.

Bridgefront Capital first reported a position in NUVL in Q1 2025 and held it in 1 quarter. The position peaked at $358K in Q1 2025. 209 funds tracked by Wall St. Rank hold NUVL as of Q2 2025.

Bridgefront Capital reported no remaining Nuvalent position as of Q2 2025 after selling out during the quarter.
Bridgefront Capital sold 5,053 Nuvalent shares in Q2 2025, an estimated $358K.
Bridgefront Capital first reported a position in Nuvalent in Q1 2025 and held it in 1 quarter.
Bridgefront Capital's Nuvalent position peaked at $358K in Q1 2025.
209 funds tracked by Wall St. Rank held Nuvalent as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.